Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...
A simulation study suggests that routine use of multicancer early detection tests could cut stage IV diagnoses of 14 cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback